Research programme: monoclonal antibodies - Jinghua Pharmaceutical/Kadmon CorporationAlternative Names: Anti-VEGFR2 and anti-PD-L1 monoclonal antibodies - Jinghua/Kadmon
Latest Information Update: 02 Dec 2015
At a glance
- Originator Kadmon Corporation
- Developer Jinghua Pharmaceutical; Kadmon Corporation
- Class Monoclonal antibodies
- Mechanism of Action CD274 antigen inhibitors; Vascular endothelial growth factor receptor-2 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer